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INTERSPECIES  SPLEEN-MYELOMA  HYBRID 
PRODUCING  MONOCLONAL  ANTIBODIES  AGAINST 
MOUSE  LYMPHOCYTE  SURFACE  GLYCOPROTEIN,  T200" 
BY IAN S. TROWBRIDGE 
(From the  Department of  Cancer  Biology,  Salk Institute  for  Biological  Studies,  San Diego, 
California, 92112) 
Fusion  of  myeloma cells  and  normal antibody-forming  cells  (I,  2)  can  be  used 
to  obtain  cell  hybrids  producing  specific  monoclonal  antibodies  against  individ- 
ual cell  surface  differentiation  antigens  (3-5).  We have previously  identified  a 
large surface glycoprotein on mouse thymus-derived cells referred to as T200 
that  is  a  major  differentiation  antigen  of mouse  lymphoid tissue  (6-8).  We 
report here the selection of a rat spleen cell-mouse myeloma hybrid producing 
monoclonal antibodies to this molecule. 
Materials and Methods 
Cell Lines.  The cell lines used in these studies were S194/5.XX0.BU.1, a bremedeoxyuridine- 
resistant mutant of a  mouse myeloma that originally secreted IgA but now is a  nonpreducer 
(kindly provided by Dr.  R.  Hyman, Salk Institute), T1M1 (Thy-l-c), a Thy-1- mouse thymus- 
derived (T) lymphoma, BWS147.G.1.40uaa.1 and $49.1.T.2.3, Thy-1 ÷ T lymphomas referred to as 
BW5147 (Thy-1  +) and $49 (Thy-l+), respectively, RAW253.1.TB.1, an Abelson virus-induced cell 
line,  S194/2.C.M.D.3.3.3  (kindly  provided  by  Dr.  W.  Raschke,  Salk  Institute),  and 
MPC.11.TG.7.OuaR.1,  two  mouse  myelomas.  Cells  were  maintained in  Dulbecce's  modified 
Eagle's medium supplemented with 10% fetal calf serum. Details of the origin and some of the 
properties  of  these cell  lines  can be found in  references  9-11. 
Cell Fusion.  S194/5.XX0.BU.1  myeloma  cells (10  ~) and spleen cells (10  s) from Lewis rats 
immunized by 4-6 i.p. injections  of 1-4 ×  107 TIM17  (Thy-l-c) or BW5147  (Thy-1  +) lymphoma 
cells  were fused with polyethylene glycol  1500 (BDH lot  6022810, 35 or 40% vol/vol)  3-5 days after 
the rats  had been given their last  immunization (3).  Cell hybrids were selected  in HAT  medium 
and their  production of  antibodies against the lymphoma cells  used for immunization was tested 
by an antibedy.binding  assay essentially  as described by Williams et al. (4).  Hybrid cells  were 
cloned by the method of limiting dilution  in Falcon microtiter plates (BioQuest, BBL &  Falcon 
Products, Becton, Dickinson & Co., Cockeysville, Md.) (Catalogue no. 3040). 
Antibody Binding Assays.  Rabbit IgG antibodies against rat IgG were purified by affinity 
chromatography and gel filtration and then labeled with 1~I (12). Trace binding assays (rabbit 
anti-rat IgG antibodies, -25  ~Ci/pg,  1.68  x  106 cpm/assay) were used to detect cell hybrids 
producing antibodies against mouse lymphoma surface antigens and saturation binding assays 
(rabbit anti-rat IgG antibodies at 100/zg/ml, 0.4 pCi//~g) were used to estimate the number of 
antibody binding sites per cell (13). The number of anti-rat IgG antibodies bound per rat IgG 
molecule on the cell surface under these conditions was determined by a radioimmune assay as 
described previously (13). 
Biochemical  Methods.  Lactoperoxidase-catalyzed  cell surface iodination, immunoprecipita- 
tion techniques, and sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 1 
* Supported by grant CA 17733 from the National Cancer Institute. 
Abbreviations used in this paper: B, thymus-independent;  Mr, molecular weight; SDS-PAGE, 
sodium dodecylsulphate-polyacrylamide  gel electrophoresis;  T, thymus-dependent. 
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were performed as described previously (6-8).  To analyze the secreted products of cell hybrids, 
cells (5  ×  105/ml) were incubated for 24 h  with [3H]leucine  (50  ~tCi/ml) in Dulbecco's modified 
Eagle's medium and the labeled Ig in the supernates was isolated by immunoprecipitation and 
examined by SDS-PAGE. The concentration of antibody in culture supernates was estimated by a 
radioimmune assay (12) suitable for measuring rat IgG over a range of 10-400 ng. Protein was 
measured by the method of Lowry et al. (14) by using bovine serum albumin as the standard. 
Results 
Selection of Cell Hybrids.  Using a  cell fusion procedure and subsequent 
selection conditions essentially as previously described by KShler and Milstein, 
Galfr~ et al., and Williams et al.  (1-4),  we obtained cell hybrids between the 
mouse myeloma, S194/5.XX0.BU.1,  and rat  spleen cells immunized against 
mouse lymphoma cells. At an optimal concentration of polyethylene glycol (40% 
vol/vol in these experiments), most or all of the 48 wells of the Linbro tissue 
culture plates into which the polyethylene glycol-treated cell suspensions were 
divided contained cell hybrids. 
We  tested  376  supernates from cultures of cell  hybrids  obtained from 20 
separate fusion experiments for antibodies specific for surface antigens of  mouse 
lymphoma cells by the double antibody binding assay described by Morris and 
Williams (13). Highly significant antibody binding (>3-fold background) was 
detected in  supernates from  71  cultures  (19%). We  then tested  34  of these 
supernates  for  antibodies  capable  of precipitating  labeled  molecules  from 
detergent  extracts  of lymphoma cells  labeled  by  lactoperoxidase-catalyzed 
iodination. Only one positive culture supernate was found which was from a 
cell hybrid  (designated I3/2)  derived from a  fusion between S194/5  myeloma 
cells and rat spleen cells immunized against T1M1 (Thy-l-c) cells. SDS-PAGE 
analysis of the labeled species precipitated by I3/2 supornate showed that a 
single iodinated species of apparent molecular weight (Mr) 190,000 was present 
(Fig. 1). From the apparent Mr and the amount of radioactivity associated with 
the  labeled  molecule we  tentatively  identified  this  molecule as  the  major 
lymphoid cell surface glycoprotein, T200, which we had previously studied (6- 
8).  The remaining experiments reported here were designed to test this idea 
and to characterize the I3/2 spleen-myeloma hybrid and the immunoglobulin it 
produces. 
Specificity ofi3/2 Antibody.  The specificity of I3/2 antibody and the nature 
of the surface molecules with which it reacts were investigated in several ways. 
First,  the binding of I3/2  antibodies to normal mouse lymphoid cells and a 
variety of mouse lymphoid cell lines was measured at saturating amounts of 
both I3/2  antibodies and  the  second antibody reagent  (125I-labeled,  affinity- 
purified rabbit IgG anti-rat IgG)  (Table I).  The results of these studies show 
that the antigen recognized by I3/2 antibodies is present on mouse thymocytes, 
spleen, and bone marrow cells and all the lymphoid cell lines tested except for 
MPC. ll.TG.7.Oua  R. 1 myeloma cells. 
Because of problems in measuring I3/2 antibodies in a conventional radioim- 
mune assay for rat IgG (see later), the ratio of rabbit anti-rat IgG antibodies to 
I3/2 antibodies bound to the cells under these conditions could only be deter- 
mined approximately. However the value obtained of 4:1 is similar to previous 
estimates for  the  ratio  of first  and  second antibodies in  similar  saturation IAN  S.  TROWBRIDGE  315 
FIG.  1.  Analysis of the specificity of the monoclonal  antibody secreted by I3/2 hybrid. The 
figure shows an autoradiograph (1 day exposure)  of a 10% SDS-polyacrylamide gel of the 
labeled antigen precipitated by I3/2 antibodies from a detergent extract of T1M1 (Thy-1  +) 
cells previously iodinated by the lactoporoxidase  technique. Also shown for comparison is a 
similar autoradiograph of the iodinated species precipitated by serum from a rat immunized 
with T1M1 (Thy-l=) cells in exactly the same way as the donor of the spleen cells used for 
the fusion from which the I3/2 myeloma hybrid was selected. 
binding assays (13). If this ratio is accurate, then the number of antigenic sites 
for I3/2 antibodies on the surface of each lymphoid cell can be calculated to be 
either 50% or 25% of the values given in Table I, depending upon whether one 
or both binding sites of the I3/2 antibodies are occupied. From this calculation it 
can be estimated that thymocytes and spleen cells have 50,000-100,000 mole- 
cules per cell of I3/2 antigen, BW5147 (Thy-1 +) cells, 200,000-400,000 molecules 
per cell (a similar antigen density to spleen cells and thymocytes since their 
surface area is about fivefold less than that of BW5147 (Thy-1 +) cells),  while 
bone marrow cells and the other lymphoid cell lines express lesser amounts of 
the antigen. 
The detailed results of a saturation binding assay in which the binding of I3/ 316  MYELOMA-HYBRID  SECRETING  MONOCLONAL  ANTI-T200  ANTIBODY 
TABLE I 
Saturating Binding ofi3/2 Supernate to Mouse Lymphoid Tissues and Lymphoid Cell 
Lines 
Mouse lymphoid tissues 
Molecules bound per  cell  (  × 10-5)  * 
Exp. 1  Exp. 2  Exp. 3 
Tumor type 
Lymphoma 
Abelson virus induced 
Myelomas 
Thymus  1.57  2.05  2.1 
Spleen  2.85  2.35  1.7 
Bone marrow  1.42  1.19 
Mouse lymphoid cell lines 
Cell line 
BW5147  11.4  8.89  10.7  (Thy-1  +) 
T1M1 (Thy-1  c)  4.34  3.67 
{RAW253.1.TB. 1  2.72  2.27 
fMPC.11.TG.7.OuaR.1  Not detectable (<0.2) 
8194/5.XXO.BU.1  1.84  2.52 
S194/2.C.M,D.3.3.3  0.89  0.99 
* Molecules of '25I-labeled rabbit anti-rat IgG antibody bound per cell determined as described in 
Materials and Methods. 
2 antibodies to thymocytes and spleen cells was measured is shown in Fig. 2. It 
can be seen that clear saturation was obtained at quite low amounts of culture 
supernate  ([3]  Fig.  6).  The  background binding of l~I-labeled  anti-rat  IgG 
antibodies to spleen cells preincubated with tissue culture medium is higher 
than that to thymocytes. One factor contributing to the high binding of anti-rat 
IgG antibodies to mouse spleen cells in the absence of I3/2 antibody is that the 
anti-rat IgG antibodies cross-react with mouse Ig. Consequently the background 
binding to spleen cells includes specific binding of anti-rat IgG antibodies to 
immunoglobulin-bearing  cells. 
The distribution of I3/2 antigen on the nonlymphoid tissues, thymus, and 
spleen was also investigated by quantitative absorption  (Fig.  3).  Consistent 
with the saturation binding assays, spleen cells expressed slightly more antigen 
than thymocytes. Little or no absorption of I3/2  antibodies by erythrocytes, 
brain or liver was detected. However, because of the relatively large numbers of 
spleen cells and thymocytes required to absorb I3/2 antibodies, the lower limit 
of detection of I3/2  antigen was  10-20%  of the amount found on spleen and 
thymus. 
The nature of the molecules on spleen cells and thymocytes with which I3/2 
antibodies react was determined by immunoprecipitation  of  the labeled antigens 
from detergent extracts ofthymocytes, normal spleen cells, and spleen cells from 
an adult-thymectomized, irradiated and bone-marrow reconstituted mouse (B 
spleen) labeled by lactoperoxidase-catalyzed iodination (Fig. 4). It can be seen 
that I3/2 antibodies react with iodinated molecules from thymocytes and spleen 
cells in the mol wt range of about 190,000-220,000  as judged by comparison of 
their electrophoretic mobilities with that of rabbit skeletal muscle myosin (Mr 
200,000).  Three labeled components from normal spleen were resolved on the 
gels.  The  intermediate component from normal spleen was  not found on B 
spleen cells  suggesting this  is derived from peripheral T  lymphocytes. The o ~0 
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FIG. 2.  Saturating binding of I3/2  antibodies to BALB/c mouse thymocytes and spleen 
cells.  Cells (2.5 × 10  ~) were incubated for 1 h at 0°C in a total  vol of  0.1 m] with various 
amounts of  spent culture supernate from 13/2  cells.  After washing, the target cells  were 
then incubated for I h with affinity-purified  rabbit  anti-rat  IgG antibodies (100/zg/ml; 0.4 
/~Ci/~g), washed, and the bound radioactivity  measured in a Nuclear-Chicago gamma 
counter (Searle  Diagnostics Inc.,  Subsidiary of  G. D. Searle & Co.,  Des Plains,  Ill.). 
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FIG. 3.  Relative absorption of I3/2 antibody by mouse tissues.  Equal volumes of I3/2 
antibody at a dilution which was limiting in the trace antibody binding assay were 
incubated for  I  h at  0°C with various amounts of  cells  or  tissue  homogenates prepared from 
4-  to  6-wk-old BALB/c mice. The mixtures were centrifuged and the supernates assayed in 
duplicate for residual binding in BW5147 (Thy-1  +) cells.  The figure shows the inhibition 
curves obtained and the relative  absorption of  the mouse various tissues  calculated from 
the ~g protein required for 50% absorption of I3/2 antibodies. 
slowest migrating component from normal spleen is probably derived from B 
lymphocytes since  it  is  also  found  on B spleen  cells  and is  likely  to  be  the same 
molecule previously  identified  on B-cell  lymphoblasts induced by lipopolysac- 
charide (6).  The most rapidly  migrating species  from normal spleen is only 318  MYELOMA-HYBRID  SECRETING  MONOCLONAL ANTI-T200  ANTIBODY 
FIG. 4.  Analysis of the surface molecules of thymocytes and spleen cells recognized by I3/ 
2 antibodies. The figure shows an autoradiograph (2 day exposure) of a 5-15% gradient SDS- 
polyacrylamide gel of the iodinated surface molecules of thymocytes and spleen cells from 
normal BALB/c mice and of spleen cells from an adult-thymectomized, irradiated and bone 
marrow-restored  BALB/c  mouse  (kindly provided  by  Dr.  G.  Dennert,  Salk  Institute) 
precipitated from detergent extracts of the cells by I3/2 antibody. 
reduced  slightly  on  B  spleen  cells  and  therefore  is  derived  from  either  B 
lymphocytes or a radiation-resistant lymphoid cell. One striking fact illustrated 
by Fig. 4 is that although spleen cells express more I3/2 antigen than thymo- 
cytes, the efficiency of labelling by lactoperoxidase-catalyzed cell surface iodi- 
nation is disproportionately low relative to thymocytes. This observation should 
be taken into account in the interpretation of previous studies in which the 
existence of  a high molecular weight T-lymphocyte-specific  antigen was inferred 
largely on the basis of differences in the labeling patterns of iedinated spleen 
and thymocytes (15). 
Finally,  since I3/2 antibodies bound to the surface of spleen cells it was of 
interest to determine whether this interaction inauced cell proliferation. The 
results of the mitogenesis assay performed as described in reference 16 showed 
that even at antibody concentrations sufficient to saturate all the I3/2 spleen 
cell antigens, lymphocyte mitogenesis was not induced. 
Properties ofi3/2 Hybrid Cells.  The I3/2 hybrid was selected from a fusion 
experiment in which a  suboptimal concentration of polyethylene glycol (35%) IAN  S.  TROWBRIDGE  319 
FIG. 5.  Analysis by SDS-PAGE  of  the secreted antibody of  13/2  myeloma  hybrid cells. 
[3H]leucine labeled I3/2 antibody  was  precipitated by  rabbit anti-rat IgG  serum  and 
analyzed on a 10% polyacrylamide  gel either after  reduction with 2-mercaptoethanol  or 
unreduced  in the  presence  of iodoacetamide.  The  labeled species were  visualized by 
fluorography  (3  day exposure). 
was used. Since only growth of hybrid cells was obtained in 5 of 48 wells it was 
very likely I3/2 cells arose from a single fusion event. Subclones were isolated at 
limiting dilution from I3/2 cells which had been frozen in liquid N2 and all were 
active. 
The  amount and properties of the  monoclonal antibody produced by I3/2 
hybrid cells was studied. As shown in Fig. 5, the cells produce an Ig with an Mr 
before and after reduction that suggests the secreted antibody is an IgG. The 
mouse myeloma, S194/5.XX0.BU.1,  is a nonsecreting variant of cells originally 
producing IgA (9). It is clear from Fig. 5 that I3/2 cells do not produce mouse 
IgA.  Also, no free immunoglobulin light chains are seen in the nonreduced 
sample of the  secreted immunoglobulin. This  observation and the  results of 
preliminary immunoprecipitation experiments with anti-Ig sera from which 
mouse-rat cross-reactive antibodies were removed by absorption both suggest 
that the two species of light chains resolved on SDS-PAGE are beth derived 
from rat I3/2 antibodies. Quantitative analysis of  the amount of rat IgG in spent 
culture supernate of I3/2  cells gave results that  suggested at first that the 
antibody concentration was 0.2-0.4  ~g/ml.  However, as shown in Fig.  6,  we 320  MYELOMA-HYBRID  SlcCRBTING  MONOCLONAL  ANTI-T200  ANTIBODY 
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FIG. 6.  Anomalous inhibition of I3/2 culture supernates in a radioimmune assay for rat 
IgG. Inhibition of  binding of 125I-labeled rat IgG (Miles Laboratories) by various amounts of 
rat IgG and I3/2 culture supernate at a limiting dilution of rabbit anti-rat IgG serum was 
determined in duplicate. Antigen-antibody complexes were precipitated by goat anti-rabbit 
IgG serum in the presence of carrier normal rabbit serum. @, rat IgG; O I3/2 supernate. 
found that the inhibition  curve of  I3/2  supernates had a less  steep  slope  than 
that of  normal rat IgG indicating  that the anti-rat  IgG antiserum used in the 
assay had a lower affinity  for  13/2  antibodies  than the bulk of  normal rat IgG. 
From a comparison of  the  slopes  of  the two inhibition  curves it  can  be  calculated 
that measurements  of I3/2 antibody  from the normal IgG standard curve 
underestimate the true  amount of I3/2 antibody by about fivefold. Thus the 
concentration of specific antibody in spent I3/2  culture medium is probably 
about 1-2/~g]ml. Another interesting observation was that I3/2 antibodies were 
not cytotexic in the presence of guinea pig complement and had only a modest 
cytotexic titer (50% kill at 1:256 supernatant dilution) if rabbit serum was used 
as the complement source  (R.  Hyman,  Salk Institute, unpublished results). 
Both the weak cytotoxic titer of the I3/2 antibodies and the anomalous results of 
the radioimmune assay suggested I3/2 antibodies may be a minor IgG subclass 
that fixes complement poorly. The ability of antisera (Miles Laboratories Inc., 
Miles Research Products, Elkhart, Ind.) specific for rat IgG2~, IgG2b and IgG~ 
subclasses  (17) to precipitate leucine-labeled I3/2 antibodies was tested.  The 
results  showed  that  rabbit  anti-rat  IgG~  reacted  with  I3/2  antibodies  as 
efficiently as a polyvalent anti-rat IgG serum. In contrast, goat antisera specific 
for rat IgG2~ and IgG~ did not precipitate more radioactivity than the control 
normal goat serum (Table II). It is concluded therefore that the monoclonal I3/2 IAN  S.  TROWBRIDGE 
TABLE II 
Identification of the IgG Subclass ofi3/2 Antibodies 
Antiserum  13/2  Antibody precipi- 
tated 
cprn 
Normal rabbit serum  464 
Polyvalent rabbit anti-rat IgG  21,382 
Rabbit anti-rat IgG2b  20,363 
Normal goat serum  5,028 
Goat anti-rat IgGsa  3,628 
Goat anti-rat IgG2c  4,063 
Secreted  [3H]leucine-labeled I3/2 protein was isolated from culture 
supernates by gel filtration  on Biogel  P-10. Samples of supernate 
(28,000  cpm; 0.025  ml)  were incubated with 0.1  ml of  the  antisera shown 
at dilutions  of  1:10,  1:50,  1:250,  and 1:1250  in  duplicate  tubes  containing 
0.005 ml of  the appropriate normal serum as carrier.  After 60 rain  at 
4°C antigen-antibody  complexes were precipitated by the addition of 
either goat anti-rabbit IgG or donkey  anti-goat IgG.  The washed 
precipitates  were dissolved in 0.1 ml of  10% SDS, 0.9 ml of  H20 added, 
and samples counted in a triton-toluene scintillation  mixture.  The 
results  show the  maximal radioactivity  precipitated  by  each  antiserum. 
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antibody is an IgG~ immunoglobulin. To my knowledge the ability of rat IgG~ 
immunoglobulin  to fix complement is unknown (18). 
Finally,  another question raised by the selection of a  mouse myeloma-rat 
spleen hybrid producing monoclonal antibody against a mouse lymphoid anti- 
gen is whether the hybrid expresses this antigen. 
As shown in Table I, the mouse myeloma, S194/5.XX0.BU.1, parent of the I3/ 
2 hybrid, expresses a moderate amount of the I3/2 antigen on its surface. Since 
direct binding could not be used to measure the amount of I3/2 antigen on the 
surface of the hybrid cells, we attempted to detect the synthesis of the antigen 
by metabolically labeling the cells with 3H-mannose and immunoprecipitation 
of the antigen with I3/2 antibodies. Synthesis of I3/2 antigen was not detected in 
these experiments and it is possible therefore that the selection of this cell 
hybrid  was  dependent upon the  loss  of the  antigen either  by  chromosome 
segregation or some other mechanism. 
Discussion 
The studies  of  the specificity  of  the monoclonal antibody produced by the rat 
spleen-mouse myeloma hybrid 13/2  establish  that the antibody reacts  with the 
high molecular  weight glycoprotein  of  mouse thymocytes and T cells  which we 
have previously  referred  to as  T200 (6-8).  The 13/2  antibody has enabled us for 
the first  time to determine the amount of  T200 on these cells  by an indirect 
antibody binding assay. The estimate of 50,000-100,000  T200 molecules per 
thymocyte indicates  that on a weight basis  the thymocyte plasma membrane 
contains  similar  amounts of  T200 and Thy-1 glycoproteins.  Together these  two 
glycoproteins  probably account for  a substantial  fraction  of  the  total  thymocyte 
plasma membrane  protein. The present studies have also confirmed  our 
previous conclusions  (6, 7) that B lymphocytes express high molecular weight 322  MYELOMA°HYBRID  SECRETING MONOCLONAL ANTI-T200 ANTIBODY 
glycoproteins antigenically related to T200 that have a different electrophoretic 
mobility on SDS-PAGE. 
The availability of large amounts of monoclonal antibody specific for T200 
glycoprotein is  significant for several  reasons:  purification of T200  and the 
related glycoproteins of mouse B  lymphecytes and detailed  investigation of 
their chemical and biological properties should now be possible; also studies, 
similar to those already in progress on Thy-1 glycoprotein (11), on the biosyn- 
thesis and turnover of T200 glycoprotein in cultured lymphoma cells can be 
attempted; and finally, the availability of I3/2 antibody and other lymphoid 
tissue-specific monoclonal antibodies may enable the development of highly 
specific immunosuppressive reagents  in  the  mouse.  It  is  clear  that  similar 
antibodies against human lymphocyte antigens have potential clinical use. 
Summary 
A  cell hybrid has been selected from fusion of a  mouse myeloma and rat 
spleen cells immunized against mouse lymphoma cells that  produces mono- 
clonal  antibody  against  the  mouse  lymphocyte surface  glycoprotein,  T200. 
Antibody binding assays employing the monoclonal antibody show that there 
are about 50,000-100,000  molecules of T200 glycoprotein on mouse thymocytes 
and that  similar  antigens are  present on spleen and bone  marrow but not 
detected on nonlymphoid tissues. Examination of the labeled molecules precip- 
itated from detergent extracts of spleen cells and thymocytes iodinated by the 
lactoperoxidase  technique  by  SDS-PAGE  confirm that  there  are  structural 
differences between the antigens found on B  and T  lymphocytes. The B-cell 
glycopretein consists of at least one component of apparent mol wt 220,000 on 
SDS-PAGE,  while the T-cell glycoprotein has  an  apparent  mol wt of about 
190,000. 
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